Department of Physiology, and Department of Transfusion Medicine, King George's Medical University (KGMU), Lucknow, India.
Department of Endocrinology, King George's Medical University (KGMU), Lucknow, India.
J Am Nutr Assoc. 2024 May-Jun;43(4):315-325. doi: 10.1080/27697061.2023.2284994. Epub 2024 Jan 16.
Obesity and overweight are challenging health problems of the millennium that lead to diabetes, hypertension, dyslipidemia, nonalcoholic fatty liver disease (NAFLD), and atherosclerosis. Green coffee bean exhibited significant promise in healthy weight management, potentiating glucose-insulin sensitization and supporting liver health. The safety and efficacy of a novel, patented water-soluble green coffee bean extract (GCB70® enriched in 70% total chlorogenic acid and <1% caffeine) was investigated in 105 participants for 12 consecutive weeks. An institutional review board and Drugs Controller General (India) (DCGI) approvals were obtained, and the study was registered at ClinicalTrials.gov.
Body weight, body mass index (BMI), waist circumference, lipid profile, plasma leptin, glycosylated hemoglobin (HbA1c), and total blood chemistry were assessed over a period of 12 weeks of treatment. Safety was affirmed.
GCB70 (500 mg BID) supplementation significantly reduced body weight (approximately 6%; = 0.000**) in approximately 97% of the study population. About a 5.65% statistically significant reduction ( = 0.000**) in BMI was observed in 96% of the study volunteers. Waist circumference was significantly reduced by 6.77% and 6.62% in 98% of the male and female participants, respectively. Plasma leptin levels decreased by 13.6% in 99% of the study population as compared to the baseline value. Upon completion of 12 weeks' treatment, fasting glucose levels decreased by 13.05% ( = 0.000**) in 79% of the study population. There was a statistically significant decrease in HbA1c levels in both male and female participants ( = 0.000**), while 86.7% of the study participants showed a statistically significant decrease in thyroid-stimulating hormone (TSH) levels ( = 0.000**). The mean decrease in TSH levels on completion of the treatment was 14.07% in the study population as compared to baseline levels. Total blood chemistry analysis exhibited broad-spectrum safety.
This investigation demonstrated that GCB70 is safe and efficacious in healthy weight management.
肥胖和超重是本世纪极具挑战性的健康问题，可导致糖尿病、高血压、血脂异常、非酒精性脂肪肝（NAFLD）和动脉粥样硬化。绿咖啡豆在健康体重管理方面显示出巨大的潜力，可以增强葡萄糖-胰岛素敏感性并支持肝脏健康。一种新型专利水溶性绿咖啡豆提取物（GCB70，富含 70%总绿原酸和<1%咖啡因）的安全性和有效性已在 105 名参与者中进行了为期 12 周的连续研究。该研究获得了机构审查委员会和印度药品管制总局（DCGI）的批准，并在 ClinicalTrials.gov 上进行了注册。
在 12 周的治疗期间，评估体重、体重指数（BMI）、腰围、血脂谱、血浆瘦素、糖化血红蛋白（HbA1c）和全血化学。确认安全性。
GCB70（500mg，每日两次）补充剂可使研究人群中约 97%的体重显著减轻（约 6%； = 0.000**）。研究志愿者中有 96%的 BMI 观察到约 5.65%的统计学显著降低（ = 0.000**）。男性和女性参与者的腰围分别显著减少了 6.77%和 6.62%。与基线值相比，研究人群中血浆瘦素水平降低了 13.6%。完成 12 周治疗后，研究人群中有 79%的空腹血糖水平降低了 13.05%（ = 0.000**）。男性和女性参与者的 HbA1c 水平均有统计学显著降低（ = 0.000**），而研究参与者中有 86.7%的 TSH 水平显示出统计学显著降低（ = 0.000**）。与基线水平相比，完成治疗后研究人群的 TSH 水平平均降低了 14.07%。总血液化学分析显示出广谱安全性。
本研究表明 GCB70 在健康体重管理方面是安全有效的。
